Phase II Trial of EMD 121974 [Cilengitide] for Recurrent Glioblastoma : A Clinical Trial With Tissue Correlates of Response.

Trial Profile

Phase II Trial of EMD 121974 [Cilengitide] for Recurrent Glioblastoma : A Clinical Trial With Tissue Correlates of Response.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cilengitide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2017 Status changed from completed to discontinued.
    • 19 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top